126 results about "Sinus inflammation" patented technology

The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and / or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also generally relates to pharmaceutical compositions comprising one or more active pharmaceutical ingredients, such as azelastine or pharmaceutically acceptable salts or esters thereof including azelastine hydrochloride, particularly wherein the compositions are provided in unit dosage form. In certain embodiments, the invention provides such unit dosage pharmaceutical compositions comprising azelastine hydrochloride formulated for use as nasal sprays and / or ocular solutions or drops. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g., for the symptomatic relief of a variety of allergic and non-allergic conditions, particularly conjunctivitis, sinusitis, rhinitis and rhinosinusitis. The compositions and methods of the present invention provide significant value in terms of patient acceptability, convenience, and compliance.

The invention discloses a traditional Chinese herbal preparation for treating chronic nasosinusitis, which consists of gypsum, honeysuckle, chrysanthemum, ligusticum wallichii, radix angelicae, mint, dried tangerine, figwort root, spina gleditsiae, radices sileris, radix rehmanniae, angelica sinensis, pollen, magnolia flower, Siberian cocklour fruit, platycodon grandiflorum, radix bupleuri, radixscutellariae, herba pogostemonis, radix puerariae, bighead atractylodes rhizome and liquorice, the medicines are composited to generate a synergistic effect of all the medicine efficacies, and the preparation has the effects of opening the inhibited lung-energy, dispelling pathogenic wind, clearing liver fire, cooling and activating blood, eliminating stagnation and discharging pus. The traditional Chinese herbal preparation adopts the pharmacological basis on treating chronic nasosinusitis that: by aiming at the etiological pathology of the chronic nasosinusitis, the traditional Chinese herbal preparation prevents bacteria, diminish inflammation, avoid allergic reaction, improve immunity of the organism and microcirculation, and promote tissue cell repair. The preparation of the invention not only is in accordance with the principle of medicine and health syndrome differentiation and treatment in China, but also is supported by modern pharmological study, so the curative effect is obvious; and the preparation has no toxic or side effect, stable long-term effect and convenience for taking, and is worth being popularized.

The present invention relates to new medicament combinations which contain in addition to one or more PDE4-inhibitors (1) at least one EP4 receptor antagonist (2), as well as the use thereof for the treatment of preferably respiratory complaints such as particularly COPD, chronic sinusitis and asthma.The invention relates in particular to those medicament combinations which contain, in addition to one or more, preferably one, PDE4 inhibitor of general formula 1wherein X is SO or SO2, but preferably SO, and whereinR1, R2, R3 and R4 have the meanings given in claim 1, at least one EP4 receptor antagonist (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.